Revelation Biosciences financials
$0.8140−5.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M |
| Net income | -$14.9M | -$15.0M | -$120.3K | -$10.8M |
| Net margin | — | — | — | — |
| Diluted EPS | $-23.95 | $-1052.16 | $-101.28 | $-28646.40 |
| EBITDA | -$9.0M | -$7.9M | -$8.6M | -$10.8M |
| Operating cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M |
| Free cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M |
| Diluted shares | 0.6M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $10.7M | $6.5M | $12.0M | $5.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M |
| Shareholders' equity | $8.9M | $4.7M | $6.6M | $1.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology